Home/Pipeline/Tafenoquine

Tafenoquine

P. vivax Malaria Radical Cure

Phase 3Development

Key Facts

Indication
P. vivax Malaria Radical Cure
Phase
Phase 3
Status
Development
Company

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals is a U.S.-based public biotech company (NASDAQ: SXTP) with a mission to develop and commercialize treatments for infectious diseases, particularly in the underserved tropical disease market. Its core achievement is the FDA approval and commercialization of ARAKODA® (tafenoquine) for malaria prophylaxis in adults, a product distinguished by its convenient weekly dosing. The company's strategy centers on the strategic repurposing and lifecycle management of tafenoquine for additional anti-infective indications while navigating the complex commercial and funding landscape of a micro-cap tropical disease biotech.

View full company profile

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals is a U.S.-based public biotech company (NASDAQ: SXTP) with a mission to develop and commercialize treatments for infectious diseases, particularly in the underserved tropical disease market. Its core achievement is the FDA approval and commercialization of ARAKODA® (tafenoquine) for malaria prophylaxis in adults, a product distinguished by its convenient weekly dosing. The company's strategy centers on the strategic repurposing and lifecycle management of tafenoquine for additional anti-infective indications while navigating the complex commercial and funding landscape of a micro-cap tropical disease biotech.

View full company profile